Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)

NCT02314052 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.

NCT NCT02314052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02314052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase
Phase 1/2
Overall status
Terminated
Start date
January 27, 2015
Completion date
October 11, 2016
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma